AtaiBeckley Inc, a company operating within the healthcare sector, recently provided an update and outlook for 2026 ahead of the J.P. Morgan Healthcare Conference. The company, which is listed on the Nasdaq, reported a closing share price of $3.75 on January 8, 2026. This price reflects a decline from the 52-week high of $6.75, achieved on October 19, 2025, and an increase from the 52-week low of $1.15, recorded on April 8, 2025.
AtaiBeckley Inc, known for its focus on mental health treatments, is associated with ATAI Life Sciences NV, a clinical-stage biopharmaceutical company based in Berlin, Germany. ATAI Life Sciences specializes in researching both psychedelic and non-psychedelic compounds to develop disease-modifying mental health treatments. The company serves a global customer base and is listed on the Frankfurt Stock Exchange.
The financial metrics of AtaiBeckley Inc indicate a price-to-earnings (P/E) ratio of -4.88, which suggests that the company is currently experiencing negative earnings per share. Additionally, the price-to-book (P/B) ratio stands at 5.98, indicating that the market values the company at nearly six times its book value. These valuation metrics provide insight into the company’s recent performance and its standing within the healthcare industry.
As of January 11, 2026, the close price of AtaiBeckley Inc was $3.76, with a market capitalization of approximately $1.36 billion USD. These figures highlight the company’s financial position and market perception as it continues to navigate the competitive landscape of the healthcare sector.
